https://orcid.org/0000-0002-8385-9288
References
- Attwa, M.W., et al., 2018. LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: in vivo and in vitro metabolic investigation. Journal of pharmaceutical and biomedical analysis, 160, 19–30.
- Bachman, K.E., et al., 2004. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer biology & therapy, 3 (8), 772–775.
- Burrows, N., et al., 2011. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. The journal of clinical endocrinology & metabolism, 96 (12), E1934–1943.
- Chalhoub, N., and Baker, S.J., 2009. PTEN and the PI3-kinase pathway in cancer. Annual review of pathology, 4, 127–150.
- Davies, B., and Morris, T., 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical research, 10 (7), 1093–1095.
- Ding, X., et al., 2012. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. Journal of pharmaceutical and biomedical analysis., 61, 1–7.
- Engelman, J.A., Luo, J., and Cantley, L.C., 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature reviews. genetics, 7 (8), 606–619.
- Folkes, A.J., et al., 2008. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. Journal of medicinal chemistry, 51 (18), 5522–5532.
- Raynaud, F.I., et al., 2009. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular cancer therapeutics, 8 (7), 1725–1738.
- Salphati, L., et al., 2011. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica; the fate of foreign compounds in biological systems, 41 (12), 1088–1099.
- Samuels, Y., and Velculescu, V.E., 2004. Oncogenic mutations of PIK3CA in human cancers. Cell cycle, 3 (10), 1221–1224.
- Sarker, D., et al., 2015. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clinical cancer research, 21 (1), 77–86.
- Wallace, B.D., et al., 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 330 (6005), 831–835.
- Yip, L.Y., et al., 2018. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology, 67 (1), 282–295.